Visit us at Booth 30 | March 18 – 19, 2025 | ExCel | London, UK
As a provider of high-quality reagents and precision analytical technology, coupled with our extensive expertise in cell and gene therapy, Bio-Techne is primed to partner with you as you develop novel therapies.
Whether you are looking to accelerate your research, minimize variability in your process, scale up manufacturing, or transition to GMP-grade raw materials, we can assist you. Join us at Advanced Therapies 2025 in London and learn how we can simplify your journey from discovery to commercialization.
What’s On at Advanced Therapies Congress
Featured Sessions | What’s New | Posters | Discover Free Resources
Featured Sessions at Advanced Therapies 2025
Presentation | Advancing CMT1A Gene Therapy: Innovative PMP22 Protein Quantification in Sheep Nerves
Nervosave Therapeutics is developing an AAV gene therapy to treat Charcot-Marie-Tooth Type 1A (CMT1a). This therapy works by expressing PMP22-targeted siRNA and restoring normal expression, therefore improving the disease phenotype.
In collaboration with We-Met, they sought to correlate the vector dose and molecular efficacy using high throughput Simple Western™ capillary electrophoresis technology. Through this method, reproducible PMP22 quantitation was possible, even with very small and complex tissue samples. Get key insights into this study by attending this talk!
Presented By:
Alexandre Lucas, Ph.D., Founder and Manager, We-Met at I2MC
Julie Espallergues, Ph.D., Director of Research, Nervosave Therapeutics
Date: March 18, 2025 | Time: 1:20 PM | Track: Innovation
Live Demo | Streamlining Cytokine Delivery for Scalable, Closed System T Cell Manufacturing
Learn how to achieve optimal dosing of GMP cytokines in a scalable, closed system workflow for T cell culture. Discover how ProPak™ GMP Cytokines in weldable bags, streamline and de-risk cell culture, minimizing risks of error and contamination. See how this approach enhances both scalability and safety in T cell therapy production.
Live Demo | Rethink Your ELISA with Ella
Explore a highly sensitive, fully automated ELISA platform, perfect for QC release, that delivers reproducible data in 90 minutes. Sign up today and join us for a live demo at Advanced Therapies!
Posters at Advanced Therapies 2025
Preclinical CAR-T Cell Target Safety, Biodistribution, and Tumor Infiltration Analysis Using RNA In Situ Hybridization (ISH) Technology
The high potency of CAR-T cells demands a more stringent safety assessment to avoid “on-target/off-tumor” effects. This study uses RNAscope™ ISH technology to explore target expression specificity and CAR-T cell distribution and activation in xenograft and host tissues.
Poster #1 | Presented By: Romain Lebail, Spatial Biology Specialist, Bio-Techne
A Powerful Immunoassay Platform for Protein Expression Potency Testing
With a lack of fit-for-purpose potency assays, this study presents a simplified relative potency assay for AAV gene therapy using Simple Western™ capillary electrophoresis, addressing the challenges of custom assay development.
Poster #4 | Presented By: Samuel Fox, Simple Western Sales Specialist, Bio-Techne
Transposon Mediated CAR T-Cell Manufacturing with TcBuster
In this comparative study, we evaluate the generation, phenotype, and efficacy of CAR-T cells produced using various transposon systems and lentivirus, alongside TcBuster, a commercially available hyperactive transposase.
Poster #44 | Presented By: Will Gilbert, Cell & Gene Therapy Specialist, Bio-Techne
Accelerated Assessment of AAV Titer, Quality, and Protein Expression Potency with Automated Analytical Tools
Explore how insufficient throughput, resolution, sensitivity, accuracy, and reproducibility in AAV characterization can be addressed using a streamlined workflow of automated analytical tools to measure CQAs.
Poster #48 | Presented By: Louis Casini, Senior Immunoassay Sales Specialist, Bio-Techne
Optimize Cytokine Delivery for Scalable T Cell Manufacturing
Optimize Cytokine Delivery for Scalable T Cell Manufacturing
Reduce variability and risk in your T cell therapy with ProPak GMP IL-7 and IL-15 in single-use bags with weldable tubing. ProPak Cytokines are designed for easy integration into closed process workflows with no reconstitution or aliquoting required.
Grow Robust T Cell Cultures for the Clinic
Grow Robust T Cell Cultures for the Clinic
Designed to integrate seamlessly into your pre-clinical or clinical T cell therapy, this GMP T cell media formulation has been adopted by both academic and biopharma clinical programs, mitigating risk associated with IND submissions.
Attend a Live Demo at Advanced Therapies 2025
We’re running live demonstrations of our automated benchtop ELISA platform, Ella, and our scalable, closed system workflow for T cell culture throughout Advanced Therapies 2025. Simply fill out the form below to register for a session and see these solutions in action!
Application Notes
- Quantify Secreted T Cell Activation Markers
- Lentiviral Vector Analysis for Cell and Gene Therapy Made Simple
- G-Rex® Fill-and-Forget T Cell Manufacturing Workflow: Touch-free T Cell Expansion
- Analytical Tools to Evaluate CAR-T Cell Signaling & Activation
- Driving CAR-T Therapy to Market in the Fast Lane
- Automation Advancements in Immune Cell Therapy Workflow: IFN-gamma QC Release Testing
- Fast and Reproducible Adeno-Associated Virus Vector Titration with Simple Plex Assays on Ella
Webinars
- Streamlining Immune Cell Therapy Manufacturing Workflows with Process-Sized Cytokine Vials
- Protein Analytics Strategies for Gene Therapy - From Viral Vector Characterization to Clinical Trials
- Automated Immunoassay Platforms for Enhancing AAV Research
Blogs
- Consistency is Critical: Standardization and Quality Control Frameworks for Immune Cell Therapy Development
- GMP Raw Materials: Meeting the Demand for Cell Therapy
- 3 Steps Toward Cell and Gene Therapy Commercialization
- Strengthening Your CAR Toolkit: Analyzing CAR Expression During CAR-T and NK Cell Therapy Development
- Developing Innovative CAR T Cell Therapies to Treat Solid Tumors